Clinical trial
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at…
NCT00388440 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00388440 |
|---|---|
| Title | Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. |
| Official title | Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rubella, Mumps, Measles |
| Intervention type | Biological |
| Interventions | MMR vaccine (Priorix) |
| Enrollment | 150 |
| Start date | Nov 1, 2000 |
| Primary completion | Apr 1, 2001 |
| Completion | Apr 1, 2001 |
| First posted | Oct 16, 2006 |
| Last update posted | Sep 20, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: